ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained

H.C. Wainwright analyst Andrew Fein has maintained their neutral stance on ARCT stock, giving a Hold rating on May 11.

Andrew Fein has given his Hold rating due to a combination of factors that keep the ARCT story balanced between promise and uncertainty. He underscores that ARCT-032, the key cystic fibrosis asset, still lacks consistent, demonstrable improvement in lung function measures, and that the ongoing 12-week Phase 2 trial mainly serves as a critical test of whether longer dosing can turn earlier imaging signals into clear clinical benefit.

Fein also notes that the exit of a competing inhaled CFTR mRNA program simplifies the future competitive landscape but does nothing to raise confidence that ARCT-032 will ultimately work. With the upcoming 12-week data viewed as a binary de-risking event and ARCT-032 still characterized as a high-risk, early-stage program, he sees limited basis for a more constructive stance and therefore maintains a neutral view with an unchanged $9 price target.